#1BEAUTYHEALTH™ Q4 & FY 2022 Earnings Presentation February 28, 2023#2Disclaimer This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward-looking words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "outlook," "forecast" and other similar expressions. These are intended to identify forward-looking statements. All forward- looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company's judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2022 and other filings with the Securities and Exchange Commission. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise. Non-GAAP Financial Measures In addition to results determined in accordance with accounting principles generally accepted in the United States of America (GAAP), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted net income, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes. We believe these non-GAAP financial measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to non-recurring, unusual items. Management uses adjusted gross profit and adjusted gross margin to measure profitability and the ability to scale and leverage the costs of Delivery Systems and Consumables. The continued growth of Delivery Systems is expected to improve adjusted gross margin, as the sale of additional Delivery Systems will increase our recurring Consumables net sales, which has higher margins. Management believes adjusted gross profit and adjusted gross margin are useful measures to the Company and its investors to assist in evaluating operating performance because they provide consistency and direct comparability with past financial performance and between fiscal periods, as the metrics eliminate the effects of amortization and depreciation, which are non-cash expenses that may fluctuate for reasons unrelated to overall continuing operating performance, and other one-time or non-recurring items such as write-offs of discontinued product non-recurring program logistics and service costs. djusted gross margin has been and will continue to be impacted by a variety of factors, including the product mix, geographic direct vs. indirect mix, the average elling price on delivery systems, and new product launches. Management expects adjusted gross margin to fluctuate over time depending on the factors described above. Management uses adjusted net income (loss), adjusted EBITDA and adjusted EBITDA margin to facilitate internal comparisons of historical operating performance on a more consistent basis and uses these measures for business planning purposes. Management also believes this information will be useful for investors to facilitate comparisons of operating performance and better identify trends in the business. Management expects adjusted EBITDA margin to increase over the long-term, as the Company continues to scale and achieve greater operating leverage. The Company calculates adjusted net income as net income (loss) adjusted to exclude: change in fair value of public and private placement warrants; change in fair value of earn- out shares liability; amortization expense; loss on disposal of assets; stock-based compensation expense; interest income; other expense, net; management fees incurred from historical private equity owners; transaction related costs (including transactions costs with respect to the Business Combination), non-recurring patent litigation fees; reorganization fees such as employee severance, executive recruiting fees and executive signing bonuses; other non-recurring and one-time fees such as Syndeo initial program logistics and service costs and refinancing costs associated with amending our credit agreement; and the aggregate adjustment for income taxes for the tax effect of the adjustments described above. The Company calculates adjusted EBITDA as net income (loss) adjusted to exclude: change in fair value of public and private placement warrants; change in fair value of earn-out shares liability; amortization expense; loss on disposal of assets; stock- based compensation expense; interest income; other expense, net; management fees incurred from historical private equity owners; transaction related costs (including transactions costs with respect to the Business Combination), non-recurring patent litigation fees; reorganization fees such as employee severance, executive recruiting fees and executive signing bonuses; other non-recurring and one-time fees such as Syndeo initial program logistics and service costs and refinancing costs associated with amending our credit agreement; and the aggregate adjustment for income taxes for the tax effect of the adjustments described above; depreciation expense; interest expense; net foreign currency (gain) loss, net; and the remaining benefit for income taxes. The Company does not provide a reconciliation of its expected fiscal 2023 or fiscal 2025 adjusted EBITDA to net income (loss), the most directly comparable forward looking GAAP financial measure, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash stock-based compensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's expected fiscal 2023 and fiscal 2025 net sales and adjusted EBITDA is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. 2 BEAUTYHEALTH™#3Today's agenda 3 Opening remarks Andrew Stanleick President & Chief Executive Officer Q4 & FY 2022 results & FY 2023 outlook Liyuan Woo Chief Financial Officer Q&A BEAUTYHEALTH™#4Andrew Stanleick President & Chief Executive Officer Opening remarks BEAUTYHEALTH™#5Beauty Health delivered strong top-line growth in 2022 and EBITDA in line with guidance Eight consecutive quarters of double-digit topline growth 100 $98.1mm Q4 2022 net sales +26% growth YoY LO $16.3mm Q4 2022 adjusted EBITDA¹ +92% growth YoY ($3.8mm GAAP net income) 5 Double-digit YoY growth across all regions FY 2022 YoY growth: Americas: +44% APAC: +24% EMEA: +46% Global: +41% +48% 2018-2022 revenue CAGR² Outsized investment years now largely complete 1. Non-GAAP measure; refer to the disclaimer for a discussion of the definition of this measure and appendix for reconciliation to the most appropriate GAAP measure. 2. Excludes 2020 due to impact of COVID. Global infrastructure ready to scale Positioned to drive profitable growth in 2023 and beyond Continued momentum, confirms 2025 net sales and adjusted EBITDA margin targets BEAUTYHEALTH™#6In 2023, our focus is profitable growth, optimization, and building the product portfolio Build the portfolio 6 2Q international Syndeo launch 1600 Expanding our connected platform globally Boosters, complementary products and services. $450 - $470mm 2023E net sales +23 - 28% YoY growth Harness reopening of China Maintain gold standard positioning in market 18 - 20% 2023E adjusted EBITDA margin¹ +497 - 697bps margin expansion 1. Adjusted EBITDA margin is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook. BEAUTYHEALTH™#7Continued progress against our 5-point Master Plan 7 al C Expand footprint, drive consumables 2 Tht Invest in providers 3 Drive brand awareness 8 (50) Optimize global infrastructure G 5 S M&A BEAUTYHEALTH™#8Achieved another year of record delivery system sales. and recognition as estis' favorite treatment & device. 8 Choice 2023 Restheticians dermascope AWARDS WINNER Winner of TWO Aestheticians' Choice Awards Hydrodermabrasion Machine: Syndeo Favorite Signature Treatment: Hydrafacial 4,103 3,943 160 2019 New Systems Trade-Ups 2,647 2,602 45 6,191 5,950 +37% 2021 241 8,492 1,793 2020 Booming beauty health category offers expansive and still under-penetrated growth runway 6,699 2022 BEAUTYHEALTH™#99 BEAUTYHEALTH™ Expected launch date Q2 2023: EMEA, APAC Q4 2022: Canada, Q1 2023: Mexico, expansion International Q1 2023: US / EMEA First prestige skincare partner Q1 2023: US / EMEA consumables growth Harness demand to fuel JLO BEAUTY bylalargal 13a (50 ml) p 17 (50) LO BEAUTY BOOSTER Omorovicza, ADVANCED SKIN RENEWAL YES OFF Delivered by HydraFacial hydrafacial Delivered By JLO BEAUTY Delivered by HydraFacial Net 9 ml / 0.30 % z U.S. Omorovicza, ADVANCED SKIN RENEWAL Omorovicza LO BEAUTY Polyf Delivered by Hydrofacial Omorovicza, ADVANCED SKIN RENEWAL ADVANCED SKIN RENEWAL Net 9 ml / 0.30 U.S. Ne m/0.30 Bor U.S. Ner 9 ml/0.30 flor U.S. ADVANCED SKIN RENEWAL y HydraFacial Net 9 ml / 0.30 oz U.S. JLO BEAUTYⓇ BUDAPEST Omorovicza. Hydrabody expanded booster portfolio and treatment offerings Driving consumables and recruiting consumers with#10Engaging providers with disruptive trade show presence. Hydrafacial 10 tcomes 2tim smoother skin paired with RF or focused Hydrafacial Outstanding client satisfaction 100% of clients would recommend Hydrafacial to their family or friends" Hydrafacial Powerful partnerships Hydrafaciar Hydrafacial Get the best skin of your life.* One device. Endless possibilities for your business. Level 1, Booth No. P1889 svetil Trade show presence IMCAS 2023 | Paris Hydrafacial 'ydrafacial Hydrafac CAST/AY TAYAYZZAR Hydra Hybrid 14P KOL & influencer reception BEAUTYHEALTH™ AND#11Accelerating brand awareness, trial and affinity $14.6 Earned media value¹ ($mm) 11 $5.6 Jan-19 FY 2019 +3% $5.8 vs 2019 Jul-19 FY 2020 mrwww.www Jan-20 +36% $7.9 vs 2019 Worldwide Google search trends demonstrate increasing consumer and provider interest www. тим FY 2021 I ww FY 2022 Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Interest over time ---2021 average Source: Tribe Dynamics and Google. 1. Earned Media Value is a proprietary metric published by Tribe Dynamics used as an influencer marketing metric to quantify the value of social media content. Delivered exponential EMV growth $14.6mm +85% YoY +23% YoY search trend growth BEAUTYHEALTH™#12Leading with science, scaling with celebrities From peer-reviewed clinicals... Acne clinical study in Journal of Clinical and Aesthetic Dermatology JCAD VOL 15, NO 12 DECEMBER 2022- JCADONLINE.COM LIVE FECTA 12 CA LIVE 15 YEARS JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY hydrafacial New York, New York Hydrafacial for Acne NEW CLINICAL STUDY Finds Hydrafacial clarifying treatments improve acne skin concerns W 43 Liked by jessgermann and 1,406 others hydratacial Do you struggle with acne? Fresh findings from a new stucy just dropped in the Journal of Clinical and Aesthetic Dermatology that show just how...more View all 58 comments thebeautysaint Pure magic for skin! savannahshore Finally got my first hydrafacial with clarifying booster for my birthday and I con definitely see the difference in my acne and skin. n Q Ö Ⓒ NEWBEAUTY Exclusive: 100% of People Have Clearer Skin After This Facial Where do we sign up? "Come for the clear skin, stay for the confidence boost." ...to influencer and celebrity endorsements Celebrity and influencer seeding program karrueche 170 posts karrueche ™M Actor Follow 13M followers Message 1,280 following @thebaytheseries @amprgroup @staym88 nbed VOGUE 2022 56 FRANCE N'1033 Lily Collins à Paris BEAUTYHEALTH™ cogne.fr I discovered the Hydrafacial when I was working in France. I really saw the difference. My skin has never felt so clean and glowing. 55#13Dior powered by Hydrafacial: reaching new consumers with elevated spa and retail experiences 13 D UTIONS PROFESSIONNELLES DIOR Peeling Floral DIOR LES SOLUTIONS PROFESSIONNELLES Lotion Peeling Floral Visage et Corps DIORA Lotion Peeling Floral Visage et Corps DIOR LES SOLUTIONS PROFESSIONNELLES Lotion Peeling Floral Visage et Corps DIORd by d Pun Delivered by PROFESSIONNELLES a un Available exclusively at Dior spas around the world from April 2023 sdion sa abes BEAUTYHEALTH™#14Infrastructure buildout largely complete, ready to scale Key 2022 investments Fortified leadership team → Opened key experience centers in New York, London, Paris and Singapore → Elevated branding and awareness initiatives → Enhanced marketing collateral for providers → Local production in China, 3PL in EMEA → Global ERP, CRM & SOX implementation 14 O 4 Significant opportunity to generate margin expansion via fixed cost leverage € ! 海菲秀 BEAUTYHEALTH™#15Our vision is to accelerate through M&A Differentiated product or service / high Net Promoter Score Integrate and realize synergies 15 Identify gaps in portfolio ● Acquire digestible asset Complementary to our existing platform and community, leveraging the trusted esthetician Financially attractive profile via compelling revenue growth, recurring revenue characteristics and / or profitability No predetermined timeline for transaction Prudent approach and opportunistic philosophy rather than time-based 5 BEAUTYHEALTH™#16Building the portfolio with the acquisition of microneedling device SkinStylus Highly complementary addition to Beauty Health portfolio with compelling commercial opportunity FDA-cleared with credibility as an esthetician- founded brand, deepening our trust and relationship with the core of our community Multiple cartridges, patented system and superior user experience are differentiators in the category Smaller size and sales force familiarity with category makes an ideal candidate for seamless integration 16 5 SkinStylus BEAUTYHEALTH™#17Liyuan Woo Chief Financial Officer Q4 & FY 2022 results & 2023 outlook BEAUTYHEALTH™#18Q4 & FY 2022 financial highlights Net sales by segment ($mm) % YoY growth Systems Consumables Net sales 18 $47.5 21.9 25.7 Q1 212 51% 23% 37% Delivery Systems Consumables Trade-Ups¹ $66.5 $68.1 31.6 32.0 34.9 36.2 $77.9 35.2 42.7 33.8 $103.5 23.3 $75.4 : $80.2 41.6 38.8 $88.8 41.5 39.7 Q2 21² Q3 21² Q4 21² Q1 22 Q2 22 67% 90% 74% 62% 85% 36% 48% 55% 39% 54% 23% 57% 72% 56% 59% 56% 30% $98.1 49.1 50.7 Q3 22 47.4 Q4 22 19% 24% 35% 26% 1. Trade-Up revenue only disaggregated in Q2 22. 2. Year-over-year growth for 2021 periods is compared to 2019. The Company believes 2019 is a more meaningful comparison than 2020 given the pandemic disruption in 2020. Delivery Systems Consumables $112.3 55.2 57.1 2018 $166.6 85.2 81.5 2019 43% 54% 48% $119.1 65.7 53.4 $260.1 120.6 139.5 2021² 2020 (34%) 71% (23%) 42% (29%) 56% $365.9 159.6 206.2 2022 48% 32% 41% BEAUTYHEALTH™#19Q4 & FY 2022 financial highlights (cont'd) Net sales by region ($mm) % YoY growth Americas APAC EMEA Total 19 Americas EMEA $47.5 7.5 8.8 31.3 $66.5 11.4 12.4 42.7 APAC Trade-Ups¹ $68.1 12.6 10.5 45.0 $77.9 $75.4 15.5 12.0 50.4 17.9 12.9 44.6 Q1 21² Q2 21² Q3 212 Q4 212 Q1 22 18% 34% 51% 252% 344% 218% 29% 47% 43% 64% 47% 84% 140% 56% 46% 94% 37% 57% 72% 59% $103.5 23.31 980.2 15.3 17.8 10.4 $88.8 52.1 15.1 58.4 Q2 22 Q3 22 77% 30% (17%) 44% 56% 56% 30% 21% $98.1 17.3 15.9 64.9 Q4 22 29% 33% 12% 26% 1. Trade-Up revenue only disaggregated in Q2 22. 2. Year-over-year growth for 2021 periods is compared to 2019. The Company believes 2019 is a more meaningful comparison than 2020 given the pandemic disruption in 2020. $112.3 Americas APAC 1.4 6.3 88.7 2018 $166.6 28.4 15.8 122.4 2019 38% 152% 64% 48% $119.1 23.2 14.5 81.5 EMEA $260.1 47.0 43.7 169.4 $365.9 68.3 54.3 243.2 2020 2021² 2022 (33%) 38% 44% (8%) 177% 24% (18%) 65% 46% (29%) 56% 41% BEAUTYHEALTH™#20Q4 2022 key performance indicators 25,336 2,067 $24,408 $50.7mm Delivery system revenue +19% YoY $47.4mm 20 1. Average Selling Price. Net global install base +24% YoY Delivery systems sold Q4 +12% YoY Delivery system ASP¹ +8% YoY Consumables revenue +35% YoY Edit Treatment Deluwe HydraFacial Exfoliation instructions and spread o Ang 60% opping Make Device To hydrafacial Serim Ade4 ACTIV-4 Treatment Pattern Dalang ft Overlang Step 1 Step 4 Step BETA HD CLEAR ANTICE ! BETA-HO CLEAR INSEAWAY 14 ! ANTION e ANSEAWAY BEAUTYHEALTH™#21Measuring consumables revenue Consumables revenue by quarter ($mm) 21 $21.9 $31.6 $32.0 $35.2 $33.8 $38.8 $39.7 $47.4 1021 2021 3Q21 4021 1022 2022 3Q22 4Q22 % YoY growth 23%1 48%1 55%1 39%1 54% 23% 24% 35% Quarterly consumables revenue correlation with new systems sold (2019, 2021 & 2022) $55 Consumables revenue ($mm) $45 $35 $25 $15 750 1,000 R² = 0.9029 1. Year-over-year growth for 2021 periods is compared to 2019. The Company believes 2019 is a more meaningful comparison than 2020 given the pandemic disruption in 2020. 1,250 1,500 New Delivery Systems Sold 1,750 2,000 Accelerated delivery system placements expected to continue driving consumables growth BEAUTYHEALTH™#22Q4 & FY 2022 financial highlights Gross margin and adjusted gross margin¹ 22 72.9% Q4 2021 66.4% 69.9% Gross margin Q4 2022 2 68.4% 2 FY 2021 FY 2022 Gross margin 76.5% 72.3%² Q4 2021 Q4 2022 Adjusted gross margin¹ 74.1% 2 73.0%² FY 2021 FY 2022 Adjusted gross margin¹ Net income (loss) and adjusted net income (loss)¹ ($mm) $9.1 ($375.1) FY 2021 FY 2022 Net income (loss) Adjusted EBITDA¹ ($mm) $16.3 $8.5 $44.4 10.9% Q4 2021 16.6% Q4 2022 % margin 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure. 2. Q4 2022 and FY 2022 gross margin impacted by trade-up volumes, Syndeo initial program logistics and servicing costs, raw material write-offs, warranty reserves, global supply chain challenges, inflationary pressures and foreign exchange headwinds $4.5 FY 2021 FY 2022 Adjusted net income (loss)¹ $32.7 12.6% FY 2021 $47.7 13.0% FY 2022 BEAUTYHEALTH™#23Understanding our seasonality Sequential net sales growth by calendar quarter +50% +40% +30% +20% +10% 23 0% (10%) -FY 2021 Q1 Q2 Sequential decline vs. Increase vs. Q4 - returns from Q1 as leads vacation, recently convert completed capex cycle FY 2022 03 Summer seasonality impact Q4 Holiday promotions, seasonal peak % adjusted EBITDA contribution by quarter¹ Back-half weighted China zero- COVID policy impact consumer consumption and capex spending lead to highest $ net sales quarter of the year Skewed by COVID 21% 35% 18% FY 2021 Note: numbers may not sum due to rounding. 1. Adjusted EBITDA is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information regarding the assumptions underlying. 2. Q3 2022 vs Q2 2022 net sales growth excludes $23.2mm net sales from trade-ups to new Syndeo system in Q2 2022. 26% 5% 27% 35% 34% FY 2022 Q2 Q3 Q4 BEAUTYHEALTH™#24Q4 2022 cost detail ($mm) Gross Profit Selling & Marketing G&A R&D 24 Q4 2022 Q4 2021 Δ Q4 2021 Q4 2022 $65.2 39.0 28.5 1.4 $56.8 37.1 25.0 1.9 +$8.4 +2.0 +3.4 (0.4) 66.4% 39.8% 29.0% 1.5% % net sales Q4 2021 72.9% 47.6% 32.2% 2.4% Δ Q4 2021 Δ Commentary (6.5%) (7.8%) (3.1%) (0.9%) Trade-up volumes, Syndeo initial program logistics and servicing costs, raw material write-offs, warranty reserves, global supply chain challenges, inflationary pressures and foreign exchange headwinds Increases in sales commissions associated with higher revenues partially offset by leverage of fixed marketing investment Increase in stock-based compensation, personnel-related expenses and professional fees relating to SOX implementation, partially offset by fixed cost leverage Lapping of Syndeo development costs, partially offset by investments in data infrastructure BEAUTYHEALTH™#25Q4 2022 balance sheet highlights Cash and cash equivalents Warrants Convertible debt Revolving credit facility Shares outstanding 25 → Approximately $568.2 million cash and cash equivalents on balance sheet Approximately 7.0 million Private Warrants outstanding $750.0 million 1.25% convertible notes due 2026 → Use of proceeds: capped call transaction, potential future acquisitions, working capital expenditures, and general corporate purposes → Conversion price of $31.76; capped call agreement provides dilution protection up to $47.94 $50.0 million Senior Secured Credit Facility remains undrawn; current undrawn commitment fee of 25 bps Allows flexibility for future M&A; ex-US operations unencumbered; convertible debt excluded from covenants → Approximately 132.2 million current shares outstanding First $100 million accelerated share repurchase program completed; approximately 9.3 million shares retired → Second $100 million accelerated share repurchase program expected to be completed by the end of Q2 2023 BEAUTYHEALTH™#262023 outlook: increasing operating leverage and accelerating China 26 $450mm to $470mm 2023E net sales +23 - 28% YoY growth Clear path to 18% - 20% adjusted EBITDA margin¹ 13.0% International launch of Syndeo → Increased focus and penetration within China Expansion of new partners and providers in US 1. Adjusted EBITDA margin is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook; note: chart not to scale. 2022 Adj EBITDA margin 2H23 realization Opex leverage Gross margin expansion 20% 18% Potential benefit from strong China acceleration 2023E Adj EBITDA margin BEAUTYHEALTH™#27Beauty Health delivered strong top-line growth in 2022 and EBITDA in line with guidance Eight consecutive quarters of double-digit topline growth 100 $98.1mm Q4 2022 net sales +26% growth YoY $16.3mm Q4 2022 adjusted EBITDA¹ +92% growth YoY ($3.8mm GAAP net income) 27 Double-digit YoY growth across all regions FY 2022 YoY growth: Americas: +44% APAC: +24% EMEA: +46% Global: +41% +48% 2018-2022 revenue CAGR² Outsized investment years now largely complete 1. Non-GAAP measure; refer to the disclaimer for a discussion of the definition of this measure and appendix for reconciliation to the most appropriate GAAP measure. 2. Excludes 2020 due to impact of COVID. Global infrastructure ready to scale Positioned to drive profitable growth in 2023 and beyond Continued momentum, confirms 2025 net sales and adjusted EBITDA margin targets BEAUTYHEALTH™#28Andrew Stanleick President & Chief Executive Officer Liyuan Woo Chief Financial Officer Q&A BEAUTYHEALTH™#29hydrafacial drafacial TOTA hydrafacial THE BEST SKIN OF YOUR LIFE ONALISATION STATION daf @hyd afacia #hydrafacialLON Appendix hydrafac hrafa @hydrafacialuk #hydrafacialLDN BEAUTYHEALTH™#30Reconciliation of gross margin to adjusted gross margin Year ended December 31, 2022 $365.9 115.5 $250.3 68.4% ($mm) Net sales Cost of sales Gross profit (GAAP) Gross margin (GAAP) Adjusted to exclude the following: Write-off of discontinued product¹ Non-recurring Syndeo initial program logistics and service costs² Stock-based compensation expense included in cost of sales Depreciation and amortization expense included in cost of sales Adjusted gross profit Adjusted gross margin 30 Three months ended December 31, 2021 $77.9 21.1 $56.8 72.9% 2022 $98.1 33.0 $65.2 66.4% 2.4 0.2 3.1 $70.9 72.3% 0.2 2.7 $59.6 76.5% Note: Figures may not sum due to rounding. 1. Represents a one-time write-off primarily related to the discontinued Glow & Go pilot program. 2. Represents costs associated with Syndeo's US launch and international launch readiness, including premiums paid on accelerated manufacturing and shipping. 2.0 2.4 0.8 11.6 $267.2 73.0% 2021 $260.1 78.3 $181.8 69.9% 0.4 10.4 $192.6 74.1% BEAUTYHEALTH™#31Reconciliation of net income to adjusted EBITDA Three months ended December 31, 2021 Year ended December 31, 2022 $77.9 $365.9 ($17.3) $44.4 ($mm) Net sales Net income (loss) Adjusted to exclude the following: Change in FV of warrant liability Change in FV of earn-out shares liability Amortization expense Loss on disposal of assets Stock-based compensation expense Interest income Other expense, net Management fees¹ Transaction related costs² Non-recurring patent litigation fees Reorganization fees³ Other non-recurring and one-time fees4 Aggregate adjustment for income taxes Adjusted net income (loss) Depreciation expense Interest expense Foreign currency (gain) loss, net Remaining benefit for income taxes Adjusted EBITDA 2022 $98.1 $3.8 (6.8) 0.0 4.1 0.5 7.6 (5.6) 1.3 0.0 0.0 2.8 0.3 2.8 (3.4) $7.4 1.9 3.4 1.4 2.2 $16.3 16.6% 6.0 0.0 3.9 0.0 3.8 0.0 0.2 0.0 2.6 0.0 2.0 1.3 (0.9) $1.6 2.0 3.5 (0.6) 1.9 $8.5 10.9% (78.3) 0.0 15.7 5.2 28.5 (9.2) 1.7 0.0 3.1 3.8 3.6 4.9 (14.2) $9.1 7.2 13.4 3.2 14.8 $47.7 13.0% 2021 $260.1 ($375.1) 277.3 47.1 13.3 0.0 12.4 (0.0) 4.5 0.2 34.9 0.0 2.0 2.0 (14.1) $4.5 4.5 11.8 0.1 11.9 $32.7 12.6% Adjusted EBITDA margin Note: Figures may not sum due to rounding 1. Represents quarterly management fees paid to the majority shareholder of Hydrafacial based on a pre-determined formula. Following the Business Combination, these fees are no longer paid. 2. For the three months and year ended December 31, 2022, such amounts primarily represent direct costs incurred in relation to potential acquisitions. For the year ended December 31, 2021 such amounts primarily represent direct costs incurred with the Business Combination and to prepare Hydrafacial to be marketed for sale by Hydrafacial's shareholders in previous periods. 3. For the three months and year ended December 31, 2022, such costs primarily represent executive recruiting fees, severance fees and a CEO sign-on bonus. For the three months and year ended December 31, 2021, such costs primarily represent executive recruiting and severance fees. 4. For the three months and year ended December 31, 2022, such costs primarily represent costs associated with Syndeo's US launch and international launch readiness, including premiums paid on accelerated manufacturing and shipping, and refinancing costs associated with our credit agreement. For the three months ended and year ended December 31, 2021, such costs primarily represent one-time retention awards related to the distributor acquisitions. 31 BEAUTYHEALTH™#32BEAUTYHEALTH TM